Redeye views the topline data as confirming a bell-shaped dose-response with resomelagon. While the topline DAS28-CRP improvement was not statistically significant (p=0.168), the similar secondary endpoint ACR20 was borderline (p=0.06). We view the results as supporting further development.
LÄS MER
